Orphan drugs policies: A suitable case for treatment

European Journal of Health Economics

Volumn 15, Issue 4, 2014, Pages 335-340

  Drummond, Michael ^a   Towse, Adrian ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b OFFICE OF HEALTH ECONOMICS   (United Kingdom)

Author keywords

Cost effectiveness analysis; Drug reimbursement; Health technology assessment; Rare diseases

Indexed keywords

ORPHAN DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; REIMBURSEMENT; REVIEW; TREATMENT INDICATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; MANAGEMENT; RARE DISEASES;

COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH POLICY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; ORPHAN DRUG PRODUCTION; POLICY MAKING; RARE DISEASES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84902168946     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0560-1     Document Type: Review

References (36)

1. Franco, P.: Orphan drugs: the regulatory environment. Drug Discov. Today 18, 163-172 (2013)
2. Drummond, M.F., Schwartz, J.S., Jonsson, B., Luce, B.R., Neumann, P., Sullivan, S.D.: Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int. J. Technol. Assess. Health Care 24(3), 244-258 (2008)
3. Drummond, M.F., Wilson, D.A., Kanavos, P., Ubel, P., Rovira, J.: Assessing the economic challenges posed by orphan drugs. Int. J. Technol. Assess. Health Care 23, 36-42 (2007)
4. McCabe, C, Claxton, K., Tsuchiya, A.: Orphan drugs and the NHS: should we value rarity? Br. Med. J. 331, 1016-1019 (2005)
5. Cote, A., Keating, B.: What it wrong with orphan drug policies? Value Health 15, 1185-1191 (2012)
6. National Institute for Health and Clinical Excellence.2004. Citizens council reports: ultra orphan drugs. London, NICE. http://www.nice.org.uk
7. Linley, W.G., Hughes, D.A.: Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross sectional survey of 4118 adults in Great Britain. Health Econ. 22, 948-964 (2013)
8. Desser, A.S., Gyrd-Hansen, D., Olsen, J.A., Grepperud, S., Kris-tiansen, I.S.: Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. Br. Med. J. 341, c4715 (2010)
9. Culyer, A.J.: Need: the idea won't do-but we still need it. Soc. Sci. Med. 40(6), 727-730 (1995)
10. McCabe, C, Stafinski, T., Menon, D.: Is it time to revisit orphan drug policies? Br. Med. J. 341, c4777 (2010)
11. Bridges, J.F.P., Hauber, A.B., Marshall, D., Lloyd, A., Prosser, L., et al.: Conjoint analysis applications in health-A checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health 14, 403-413 (2011)
12. Nord, E.: The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy 24, 227-238 (1993)
13. Mestre-Ferrandiz, J., Sussex, J., Towse, A.: The R&D Cost of a New Medicine. Office of Health Economics, London (2012)
14. Meekings, K.N., Williams, C.S.M., Arrowsmith, J.E.: Orphan drug development: an economically viable strategy for biophar-ma R&D. Drug Discov. Today 17, 660-664 (2012)
15. Drummond, M.F., Wilson, D.A., Kanavos, P., Ubel, P.A., Rovira, J.: Assessing the challenges posed by orphan drugs: a response to McCabe et al. Int. J. Technol. Assess. Health Care 23, 401-404 (2007)
16. Department of Health (UK): A New Value-Based Approach to the Pricing of Branded Medicines: a Consultation. Department of Health, London (2011)
17. Sussex, J., Rollet, P., Garau, M., Schmitt, C, Kent, A., Hutch-ings, A.: Multi-Criteria Decision Analysis to Value Orphan Medicines. OHE Research Paper 13/03. Office of Health Economics, London (2013)
18. Phillips, L.D., Fasolo, B., Zafiropoulos, N, Beyer, A.: Is quantitative benefit-risk modelling of drugs desirable or possible? Drug Discov. Today: Technol. 8(1), e3-e10 (2011)
19. Towse, A., Danzon, P.: The regulation of the pharmaceutical industry. In: Baldwin, R., Cave, M., Lodge, M. (eds.) Oxford Handbook on Regulation, pp. 548-571. Oxford University Press, New York (2010)
20. Kanavos, P., Nicod, E.: What is wrong with orphan drug policies? Suggestions for ways forward. Value Health 15, 1182-1184 (2012)
21. Winquist, E., Bell, CM., Clarke, J.T.R., Evans, G, Martin, J., et al.: An evaluation framework for funding drugs for rare diseases. Value Health 15, 982-986 (2012)
22. Daniels, N, Sabin, J.: Setting Limits Fairly: can we Learn to Share Medical Resources. Oxford University Press, Oxford UK (2002)
23. Clarke, J.T.R.: Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. Can. Med. Assoc. J. 174, 189-190 (2006)
24. Garau, M., Mestre-Ferrandiz, J.: Access Mechanisms for Orphan Drugs: a Comparative Study of Selected European Coun-tries.OHE Briefing No. 52. Office of Health Economics, London (2009)
25. NHS specialised services. New technologies. http://www.specia lisedservices.nhs.uk/info/new-technologies
26. NICE: Interim process and methods of the highly specialised technologies programme. http://www.nice.org.uk/media/DE4/9A/HSTCombinedInterimProcessMethods. pdf (2013)
27. Laupacis, A.: Economic evaluations in the Canadian Common drug review. Pharmacoeconomics 24(11), 1157-1162 (2006)
28. Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A.-P., et al.: Challenges in the development and reimbursement of personalized medicine: payer and manufacturer perspective and implications for health economics and outcomes research. Report of the ISPOR Personalized Medicine Special Interest Group. Value Health 15, 1162-1171 (2012)
29. Banerjee, A., Hollis, A., Pogge, T.: The health impact fund: incentives for improving access to medicines. Lancet 375(9709), 166-169 (2010)
30. Towse A, Keuffel E, Kettler HE, Ridley DB.: Drugs and vaccines for developing countries. In Danzon, P. and. Nicholson, S (eds). The Oxford Handbook of the Economics of the Biopharmaceu-tical Industry. OUP. (2012)
31. Matlin, S.A., et al. (eds.): Health partnerships review: focusing collaborative efforts on research and innovation for the health of the poor. Glob. Forum Health Res., Geneva (2008)
32. Moran, M.: A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med. 2(9), e302 (2005)
33. Berndt, E.R., et al.: Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ. 16(5), 491-511 (2007)
34. Orphanet. 2012. Prevalence of rare diseases: bibliographic data. Orphanet report series: rare diseases collection. www.orpha.net
35. Minister for health, youth and sports (France).: National strategies and action for rare diseases in Europe. Paris (2008)
36. Institute of Medicine: Rare Diseases and Orphan Products: Accelerating Research and Development. Institute of Medicine, Washington (2010)